Full-Time

Implementation Audit Analyst

User Access Management

Posted on 8/18/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Penjerla, India + 1 more

More locations: Bengaluru, Karnataka, India

Hybrid

At least three days on-site per week, with up to two remote workdays. Travel may be up to 10% domestically and internationally.

Bachelor's

Category
Accounting (1)
Required Skills
SAP Products
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Governance, Risk Management, Compliance, Audit, Information Technology, Engineering, or a related field is required.
  • At least 5 years of experience in audit or controls, compliance, or enterprise risk management is required, preferably in the Life Sciences or Pharmaceutical industry.
  • Three to five years of experience supporting IT audits, implementation audits, IT control assessments, evidence reviews, or compliance readiness activities is required.
  • Three to five years of experience with compliance frameworks including Sarbanes-Oxley, Good Practice requirements, Privacy/General Data Protection Regulation, Information Technology General Controls, and internal control standards is required.
  • Experience supporting large-scale system implementations and understanding of project lifecycle methodology, go-live readiness, operational handover, and post-go-live sustainment are required.
  • Familiarity with user access provisioning, SAP Governance, Risk, and Compliance Access Control, identity management tools, access approvals, and access review processes is required.
  • Understanding of SAP authorization concepts, SAP Security principles, role design, user lifecycle management, and access risk management is required.
  • Understanding of segregation-of-duties concepts, sensitive access risk, mitigation controls, remediation strategies, and compliance monitoring approaches is required.
  • Understanding of risk matrices, rulesets, control mapping, data analysis, data conversion, data migration, and evidence traceability is required.
  • Ability to prepare audit-ready documentation, process narratives, control evidence, policies, procedures, and governance materials with strong attention to detail is required.
  • Project management, stakeholder coordination, communication, and follow-up skills are required, including tracking risks, issues, actions, and remediation across multiple teams.
  • Fluency in English and strong written and verbal communication skills are required to communicate audit, compliance, and control topics to technical and non-technical audiences.
  • Ability to work effectively in a virtual or remote environment and collaborate with cross-functional, cross-cultural, and geographically distributed teams is required.
  • Ability to work on-site at least three days per week is required.
Responsibilities
  • Support implementation audit readiness by partnering with deployment, operational, compliance, and user access management teams to prepare governance processes, controls, and evidence requirements for each SAP S/4 go-live phase.
  • Embed audit and compliance requirements into the user access management project methodology, including control checkpoints, documentation standards, evidence retention expectations, and health checks across implementation milestones.
  • Perform implementation governance health checks covering adherence to user access management strategy, project controls, deliverable quality, remediation tracking, and readiness criteria.
  • Maintain, validate, and organize audit-ready documentation, including process narratives, control evidence, decision logs, risk assessments, approvals, issue remediation, and go-live readiness artifacts.
  • Provide implementation audit support for Sarbanes-Oxley, Good Practice requirements, Information Technology compliance, privacy, and internal control requirements, including preparing evidence packages and responses to audit inquiries.
  • Support implementation risk assessments focused on user access, segregation of duties, sensitive access, data migration, role design, provisioning, and operational handover risks.
  • Monitor compliance with user access management controls during implementation, including segregation of duties, sensitive access, emergency access, role lifecycle controls, approvals, and evidence completeness.
  • Support remediation tracking for governance, audit, and control gaps by documenting, assigning, resolving, and validating issues before go-live where required.
  • Contribute to the user access management taxonomy, control model, and service model for implementation governance, audit readiness, operational transition, and long-term sustainment.
  • Deliver audit-focused user access management governance updates, readiness summaries, and framework materials to stakeholders for SAP S/4 implementation needs.
Desired Qualifications
  • Experience in the Life Sciences or Pharmaceutical industry, particularly in regulated system implementation or compliance environments.
  • Prior experience supporting SAP Security, SAP S/4, SAP Governance, Risk, and Compliance, Identity Governance, or user access management implementation audits.
  • Demonstrated ability to support implementation audit planning, evidence collection, control validation, issue remediation, and stakeholder reporting.
  • Ability to communicate clearly, concisely, and tactfully with management, peers, auditors, project teams, and operational stakeholders.
  • Relevant certifications such as Certified Information Systems Auditor, Certified Information Security Manager, Certified Information Systems Security Professional, Certified in Risk and Information Systems Control, SAP Security, or Governance, Risk, and Compliance certifications.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance topped $101 billion.
  • TECVAYLI's March 2026 approval and TREMFYA's May expansion expand growth before 2027.
  • The July 27, 2026 talc deal removes roughly 76,000 claims and litigation expense.

What critics are saying

  • Stelara sales fell 55.7% in Q2 2026 as Amgen and Sandoz biosimilars flooded pricing.
  • The July 2026 talc settlement still depends on 95% claimant acceptance by 2027.
  • A failed talc resolution or mega-verdict forces asbestos-style reserves, capital strain, and dividend pressure.

What makes Johnson & Johnson unique

  • J&J owns leading franchises in oncology, immunology, and medtech, spanning hospitals and consumers.
  • TECVAYLI plus DARZALEX FASPRO won U.S. approval on March 5, 2026, in earlier-line myeloma.
  • TREMFYA's May 28, 2026 label now claims joint-damage inhibition, unlike rival IL-23s.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.